2.4mg Wegovy vs 10mg Mounjaro: How Do These Doses Actually Compare?

Do these two doses sit at the same point in their respective programmes?

Not quite. The 2.4mg weekly dose is Wegovy's intended maintenance dose — the level most patients reach after roughly 16 weeks of gradual titration and the dose used in the STEP 1 trial, which reported an average body-weight reduction of around 15% over 68 weeks, as published in the New England Journal of Medicine. It is where the programme stabilises for most people.

Mounjaro's 10mg dose sits differently. The schedule runs from 2.5mg up to a 15mg ceiling, so 10mg is the fourth of six available strengths, a working dose, but not the top. Patients typically reach it around week 24 to 32, depending on tolerability and prescriber guidance. If you want to understand how Wegovy compares to Mounjaro at the 10mg mark, the differences in programme position are central to reading that comparison clearly. That distinction matters when reading the numbers below.

It also matters because the medicines are fundamentally different. Wegovy is a GLP-1 receptor agonist. Mounjaro activates both GLP-1 and GIP receptors, making it the only dual agonist licensed for weight management in the UK. Whether that second pathway translates into meaningful extra benefit for a specific patient is exactly the kind of question our clinical team fields regularly.

What does the trial data show for each dose in weight loss terms?

The table below summarises the key comparators, drawing on the STEP 1 trial for semaglutide 2.4mg and the SURMOUNT-1 trial for tirzepatide. Because SURMOUNT-1 reported outcomes at 5mg, 10mg and 15mg separately, the 10mg figure is available directly.

The trial designs differ in length, population and context, so direct numerical comparison should be read carefully. The SURMOUNT-5 head-to-head trial (published in the New England Journal of Medicine in 2025) did compare tirzepatide against semaglutide 2.4mg directly, and reported greater average weight reduction with tirzepatide overall. NICE's appraisal of tirzepatide (TA1026) also notes indirect comparisons favouring tirzepatide. However, individual responses vary, and some patients do extremely well on semaglutide.

Does moving from 2.4mg Wegovy to Mounjaro make clinical sense for some patients?

Yes, and it is a question our prescribers consider fairly often. If someone has been on Wegovy at 2.4mg and has seen good tolerability but wants to explore whether a dual-agonist medicine might add further benefit, a supervised switch is a real option. The process involves clinical review, not just a simple swap, there is no established dose-equivalence table between semaglutide and tirzepatide, which is why the question of dose conversion deserves its own careful answer. For patients curious about what the 2.4mg Wegovy maintenance dose looks like alongside its Mounjaro equivalent, we cover that comparison in detail on our page about what 2.4mg Wegovy is equivalent to in Mounjaro terms.

The reverse journey is also possible. Someone on 10mg Mounjaro who is experiencing side effects they find difficult, or who has a clinical reason to change medicine, may ask about switching back to Wegovy, and patients who have reached 2.4mg on Wegovy and are weighing up that switch will find the full picture on our page covering how to move from 2.4mg Wegovy to Mounjaro. That transition carries its own considerations, detailed on the page covering moving from 10mg Mounjaro to Wegovy. Both directions require a prescriber to review your current weight, history and tolerability before anything changes.

If you are frustrated by waiting lists or uncertain which medicine even fits your situation, that feeling is entirely understandable, these are genuinely complex decisions, and the publicly available information is not always clear. A free consultation with nume... with a prescriber at nume is designed to cut through that.

What about eligibility, do both medicines have the same BMI thresholds?

Broadly yes, at private prescription level. Both Mounjaro and Wegovy are licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as hypertension, type 2 diabetes, high cholesterol or obstructive sleep apnoea. A prescriber assesses the full clinical picture, including other medicines, medical history and contraindications, BMI alone does not confirm suitability. Lower thresholds can apply for some ethnic backgrounds under UK clinical guidance.

On the NHS, the eligibility criteria differ considerably. NICE's appraisal of tirzepatide (TA1026, recommendations chapter) sets a BMI threshold of 35 or above alongside at least one qualifying comorbidity for NHS access, with phased rollout ongoing. Wegovy on the NHS is available only through specialist weight management services under NICE TA875. Private treatment through a regulated pharmacy such as nume does not require those NHS thresholds, clinical suitability is the test, assessed by a GPhC-registered Independent Prescriber. You can explore the full range of weight-loss treatment options or check what our clinical team considers on our about page.

Side effects for both medicines are largely gastrointestinal: nausea, loose stools, constipation and reflux are the most commonly reported, typically peaking after starting or after a dose increase. They tend to settle with time. Both carry the MHRA's Black Triangle (▼), meaning they are subject to additional monitoring. Any suspected side effect can be reported via the MHRA Yellow Card scheme.

Which of these medicines (and which dose) suits you is a clinical decision our prescribers make with you, not something a comparison table can settle. Check your eligibility with a free consultation today.